Moderna's CMV trial offers further upside - UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Moderna (MRNA) downgraded as HSBC skeptical on medium term INT Phase 3 data readouts
February 26, 2024 9:33 AM ESTHSBC analysts cut Moderna (NASDAQ: MRNA) to Reduce from Hold in a note Monday, raising the price target to $86 from $75 per share.
The firm said Moderna's outlook for 2024 is underpinned by prospects for its COVID-19 vaccine revenue and RSV launch. They note there are two... More
